PDF(Pubmed)
Abstract：
UNASSIGNED: Congenital syphilis (CS) is the infection of an infant or fetus with Treponema pallidum. The aim of this study was to investigate the clinical features and outcomes of serology reversion in infants diagnosed with confirmed or suspected congenital syphilis (CS).
UNASSIGNED: Infants admitted to the neonatal department of Children\'s Hospital of Fudan University from 2013 to 2016 who met the case definition of CS or suspected CS were included in this study. Follow-up was performed in an outpatient clinic until reversion to non-reactivity of both toluidine red unheated serum test (TRUST) and Treponemal pallidum particle agglutination (TPPA). Follow-up data were collected until up to the end of 2019, when the last infant with CS reached 3 years of age.
UNASSIGNED: In total, 682 infants were enrolled in this study, including 63 in the CS group and 619 in the suspected CS group. Forty-seven infants (74.6%) in the CS group had symptoms, and 57 (90.5%) had abnormal laboratory and/or long bone X-ray findings. By 6 months of age, TRUST results were negative in 53.3% of the infants with CS and in 100% of the infants with suspected CS. All the infants in the CS group returned to TRUST non-reactivity by 18 months of age. The TPPA results at 18 months of age showed that only 10.0% (3/30) of the patients in the CS group returned to non-reactivity, while a 99.6% (548/550) non-reactivity rate was observed in the suspected CS group. All the infants in the CS group returned to 19S-IgM-TPPA non-reactivity by 6 months of age.
UNASSIGNED: Although CS is an burdensome disease that may cause fetal and neonatal death, CS responds well to treatment when diagnosed and treated promptly, even when symptoms or lab/X-ray findings are present at birth.
UNASSIGNED: Infants admitted to the neonatal department of Children\'s Hospital of Fudan University from 2013 to 2016 who met the case definition of CS or suspected CS were included in this study. Follow-up was performed in an outpatient clinic until reversion to non-reactivity of both toluidine red unheated serum test (TRUST) and Treponemal pallidum particle agglutination (TPPA). Follow-up data were collected until up to the end of 2019, when the last infant with CS reached 3 years of age.
UNASSIGNED: In total, 682 infants were enrolled in this study, including 63 in the CS group and 619 in the suspected CS group. Forty-seven infants (74.6%) in the CS group had symptoms, and 57 (90.5%) had abnormal laboratory and/or long bone X-ray findings. By 6 months of age, TRUST results were negative in 53.3% of the infants with CS and in 100% of the infants with suspected CS. All the infants in the CS group returned to TRUST non-reactivity by 18 months of age. The TPPA results at 18 months of age showed that only 10.0% (3/30) of the patients in the CS group returned to non-reactivity, while a 99.6% (548/550) non-reactivity rate was observed in the suspected CS group. All the infants in the CS group returned to 19S-IgM-TPPA non-reactivity by 6 months of age.
UNASSIGNED: Although CS is an burdensome disease that may cause fetal and neonatal death, CS responds well to treatment when diagnosed and treated promptly, even when symptoms or lab/X-ray findings are present at birth.
摘要：
未经证实：先天性梅毒（CS）是指婴儿或胎儿感染梅毒螺旋体。这项研究的目的是调查诊断为确诊或疑似先天性梅毒（CS）的婴儿的血清学逆转的临床特征和结局。
UNASSIGNED：本研究纳入2013-2016年复旦大学附属儿童医院新生儿科收治的符合CS或疑似CS病例定义的婴儿。在门诊诊所进行随访，直到甲苯胺红未加热血清测试（TRUST）和梅毒螺旋体颗粒凝集（TPPA）均恢复为非反应性。收集随访数据，直到2019年底，最后一名CS婴儿达到3岁。
未经批准：总共，682名婴儿参加了这项研究，其中CS组63例，疑似CS组619例。CS组47名婴儿(74.6%)出现症状,57（90.5%）有异常的实验室和/或长骨X线检查结果。6个月大的时候,53.3％的CS婴儿和100％的可疑CS婴儿的TRUST结果为阴性。CS组中的所有婴儿在18个月大时恢复到TRUST非反应性。18月龄的TPPA结果显示,CS组只有10.0%(3/30)的患者恢复到非反应性,而在疑似CS组中观察到99.6%(548/550)的非反应率。CS组的所有婴儿在6个月大时恢复到19S-IgM-TPPA非反应性。
UNASSIGNED：尽管CS是一种累人的疾病，可能会导致胎儿和新生儿死亡，当及时诊断和治疗时，CS对治疗反应良好，即使在出生时出现症状或实验室/X射线检查结果。
UNASSIGNED：本研究纳入2013-2016年复旦大学附属儿童医院新生儿科收治的符合CS或疑似CS病例定义的婴儿。在门诊诊所进行随访，直到甲苯胺红未加热血清测试（TRUST）和梅毒螺旋体颗粒凝集（TPPA）均恢复为非反应性。收集随访数据，直到2019年底，最后一名CS婴儿达到3岁。
未经批准：总共，682名婴儿参加了这项研究，其中CS组63例，疑似CS组619例。CS组47名婴儿(74.6%)出现症状,57（90.5%）有异常的实验室和/或长骨X线检查结果。6个月大的时候,53.3％的CS婴儿和100％的可疑CS婴儿的TRUST结果为阴性。CS组中的所有婴儿在18个月大时恢复到TRUST非反应性。18月龄的TPPA结果显示,CS组只有10.0%(3/30)的患者恢复到非反应性,而在疑似CS组中观察到99.6%(548/550)的非反应率。CS组的所有婴儿在6个月大时恢复到19S-IgM-TPPA非反应性。
UNASSIGNED：尽管CS是一种累人的疾病，可能会导致胎儿和新生儿死亡，当及时诊断和治疗时，CS对治疗反应良好，即使在出生时出现症状或实验室/X射线检查结果。
